ClinicalTrials.gg
RecruitingNCT06010563PROTEUSUpdated Feb 28, 2025

VenusP-Valve Pivotal Study (PROTEUS STUDY)

An interventional study of Transcatheter pulmonary valve implantation (TPVI) and VenusP-ValveTM System in Pulmonary Regurgitation, sponsored by Venus MedTech (HangZhou) Inc.. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Venus MedTech (HangZhou) Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Pulmonary Valve Insufficiency with a site in United States — 2 open to participants now, 8 under way, none of them phase 3. Pulmonary Valve Insufficiency · United States.

Planned enrollment
7th of 10
60 · median 75
Started
2024
the only one that year
No phase
10 of 15
2 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Venus MedTech (HangZhou) Inc.

Among the 15 studies in Pulmonary Valve Insufficiency with a site in United States, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 15th registered.

Pulmonary Valve Insufficiency

31 studies on the registry are indexed under Pulmonary Valve Insufficiency; 8 are open to participants now.

Browse Pulmonary Valve Insufficiency studies →

Open to participants now

2 of the 15 studies in Pulmonary Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Pulmonary Valve Insufficiency studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pulmonary Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

A prospective, multi-center, non-randomized interventional study to evaluate the safety and effectiveness of the VenusP-ValveTM System in patients with native right ventricular outflow tract (RVOT) dysfunction.

Post procedure, a clinical visit will be scheduled at pre-discharge, 30 days, 6 months, 12 months, and annually thereafter to 10 years.

About 60 subjects will be enrolled in this study. Data analysis will be performed after all enrolled subjects complete 6-month follow-up and the primary endpoint analysis report will be submitted to FDA for PMA approval.

03

Conditions studied

  • Pulmonary Regurgitation
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Weight ≥25kg (55 lbs.)
  2. Age ≥ 12 years olds
  3. Patients have a dysfunctional native RVOT with severe pulmonary regurgitation (i.e., severe pulmonary regurgitation as determined by echocardiography or pulmonary regurgitant fraction ≥30% as determined by cardiac magnetic resonance imaging) and without significant pulmonary stenosis (significant pulmonary stenosis is defined as gradient more than 25mmHg) and are clinically indicated for intervention:
  1. For symptomatic patients, fitting the following criteria:
  • Severe pulmonary regurgitation measured by echocardiogram or pulmonary regurgitant fraction ≥30% measured by CMR 2) For asymptomatic patients, including any 2 of the following criteria:
  • Mild or moderate RV or LV systolic dysfunction.
  • Severe RV dilation (RVEDVI ≥145 mL/m2 or RVESVI ≥ 75 mL/m2or RVEDV >2 × LVEDV).
  • Progressive reduction in objective exercise tolerance. 4. Patient is willing to consent to participate in the study and will commit to completion of all follow-up requirements.

Exclusion criteria

Exclusion Criteria:

  1. Clinical or biological signs of infection including active endocarditis.
  2. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
  3. Leukopenia, anemia, thrombocytopenia, or any known blood clotting disorder, deemed after consultation with Haemato-oncology specialists.
  4. Inappropriate anatomy for femoral or right internal jugular vein (RIJ) introduction and delivery of the VenusP-ValveTM System.
  5. RVOT anatomy or morphology that is unfavorable for device anchoring.
  6. Anatomy unable to accommodate VenusP-Valve delivery system.
  7. Angiographic evidence of coronary artery compression that would result from transcatheter pulmonary valve replacement (TPVR).
  8. Emergency interventional/surgical procedures within 30 days prior to the index procedure.
  9. Planned significant and relevant concomitant procedure at time of VenusP-Valve implant.
  10. Any planned interventional/surgical procedures to be performed within the 30 days follow-up from VenusP-Valve implant.
  11. Known history of intravenous drug abuse in the past 5 years, without certificate of completion of rehabilitation from a specialist.
  12. Major or progressive non-cardiac disease resulting in a of less than one year.
  13. Known or to antiplatelet, antithrombotic medications, or nitinol (titanium or nickel) leading to be unable to undergo index procedure per physicians' judgement
  14. Positive pregnancy test at baseline (prior to CT angiography and again prior to implant procedure) in female patients of .
  15. Currently participating in an drug or another device study.
  16. Patient or guardian unwilling or unable to provide written or comply with follow-up requirements.
  17. The investigators consider that the patients are not suitable to participate in this research.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    TPVI

    Device: Transcatheter pulmonary valve implantation (TPVI) · Device: VenusP-ValveTM System

Interventions

  • DeviceTranscatheter pulmonary valve implantation (TPVI)

    A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.

  • DeviceVenusP-ValveTM System

    VenusP-ValveTM System consists of two components: 1. Transcatheter Pulmonary Valve (TPV) 2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue. For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV. The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper.

06

What researchers measure

Primary outcomes

  1. The rate of procedure or device related mortality at the 30 days follow-up visit post procedure

    Freedom from procedure or device related mortality at 30 days

    Time frame: At 30 Days Post Procedure

  2. The rate of re-intervention and acceptable hemodynamic function at 6 Month follow-up visit post procedure

    Freedom from VenusP-Valve re-intervention and acceptable hemodynamic function at 6 months defined as: 1. No more than mild regurgitation measured by CMR; AND 2. Mean RVOT gradient as measured by echocardiography ≤35mmHg.

    Time frame: At 6 Months Post Procedure

Secondary outcomes

  1. The rate of all-cause mortality, procedure or device related mortality, and procedure or device related Major Adverse Cardiac and Cerebrovascular Events (MACCE) out to 10 years

    1. Freedom from all-cause mortality, procedure or device related mortality out to 10 years 2. Freedom from procedure or device related Major Adverse Cardiac and Cerebrovascular Events (MACCE) out to 10 years 3. MACCE is defined as a non-hierarchic composite including the following procedure or device related events: 1) Stroke 2) RVOT reintervention 3) Arrhythmia 4) Coronary artery compression requiring intervention or causing myocardial infarction 5) Device-related endocarditis 6) Major stent fracture 7) Valve thrombosis 8) Valve embolization or significant malposition 9) Major vascular or access complications\* 10) Pulmonary embolism

    Time frame: Through Ten Years Post Procedure

  2. The rate of technical Success during the procedure

    Technical success at exit from catheterization lab or operating room Defined as a composite of: 1. Freedom from procedure or device related mortality 2. Successful access, delivery of the device, and retrieval of the delivery system 3. Correct positioning of the valve(s) into the proper anatomical location 4. Freedom from reintervention related to the device or to a major vascular or access-related, or cardiac structural complications

    Time frame: During the Procedure

  3. The rate of acceptable hemodynamic performance at 30 days, 1-5 years, 7 years and 10 years.

    Acceptable hemodynamic performance at 30 days, 1-5 years, 7 years and 10 years. Defined as: 1. Mean RVOT gradient ≤ 35mmHg AND, 2. No more than mild regurgitation measured by echocardiography

    Time frame: At 30 Days, 1-5 Years, 7 Years and 10 Years Post Procedure

  4. The rate of procedure success out to 30 days

    Procedure success out to 30 days, defined as follows: 1. Device success at 30 days. Defined as a composite of: * Freedom from procedure or device related mortality * Original intended device in place * No additional surgical or interventional procedures related to the procedure or the device since completion of the index procedure * Hemodynamic performance: relief of insufficiency (mild or less pulmonary regurgitation) without producing the opposite (mean RVOT gradient \> 35 mmHg) as measured by echocardiography * No new ventricular arrhythmia requiring ICD implantation 2. None of the following procedure or device related serious adverse events: * Life-threatening major bleeding * Major vascular or cardiac structural complications requiring unplanned reintervention or surgery * Stage 2 or 3 acute kidney injury (AKI) includes new dialysis * Pulmonary embolism * Severe heart failure or hypotension requiring intravenous inotrope

    Time frame: At 30 Days Post Procedure

  5. The rate of valve dysfunction out to 10 years

    Freedom from valve dysfunction out to 10 years Defined as a composite of: 1. RVOT re-intervention for device-related reasons 2. Hemodynamic dysfunction of the valve (moderate or greater pulmonary regurgitation, and/or a mean RVOT gradient \> 35 mmHg)

    Time frame: Through Ten Years Post Procedure

  6. New York Heart Association (NYHA) classification Through out to 10 years

    Functional status (New York Heart Association (NYHA) classification) out to 10 years

    Time frame: Through Ten Years Post Procedure

  7. Characterization of quality-of-life scores out to 5 year, and at 10 years

    Characterization of quality-of-life scores out to 5 year, and at 10 years As assessed by the SF-36-QOL.

    Time frame: Through Five Years Post Procedure, and at 10 Years Post Procedure

07

Study locations

1 of 1 sites recruiting
  • Venusmedtech of America
    Irvine, California 92618, United States
    Recruiting
    • Frank Zeng · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2023
First posted
Aug 24, 2023
StartActual
Jun 11, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Aug 30, 2034
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06010563
Lead sponsor
Venus MedTech (HangZhou) Inc.
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Jun 11, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Aug 30, 2034 (estimated)
Last update
Feb 28, 2025

Study contacts

Cong Ma
Contact
macong@venusmedtech.com
+8618817939751

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion